← Search & browse all drugs

sulodexide

B01AB11

Forms & Strengths

Oral capsules: 250 LSU (Lipasemic Sulfoxide Unit)
Oral capsules: 500 LSU
Solution for injection: 60 LSU/2 mL

Adult Dosing

Diabetic nephropathy / microalbuminuria: 500 LSU orally twice daily
Peripheral artery disease / intermittent claudication: 600 LSU (1 ampoule) intramuscularly or intravenously daily for 20 days, followed by 250 LSU orally twice daily for 2 months
Venous leg ulcers: 500 LSU orally twice daily as an adjunct to standard therapy

Pediatric Dosing

Safety and efficacy not established in patients under 18 years of age

Indications

Management of vascular diseases with a thrombogenic risk
Treatment of diabetic nephropathy with persistent microalbuminuria
Intermittent claudication secondary to peripheral arterial disease
Venous leg ulcers as an adjunct to compression therapy

Mechanism of Action

Purified glycosaminoglycan composed of fast-moving heparin (80%) and dermatan sulfate (20%)
Exhibits antithrombotic and profibrinolytic effects via affinity for antithrombin III and heparin cofactor II
Protects vascular endothelial cells and restores the structural integrity of the endothelial glycocalyx
Reduces blood viscosity and systemic inflammation markers

Contraindications

Known hypersensitivity to sulodexide, heparin, or heparinoid compounds
Active hemorrhagic diathesis and bleeding disorders
Patients receiving ongoing treatment with heparin or oral anticoagulants (risk of enhanced anticoagulant effect)

Adverse Reactions

Epigastric pain, nausea, vomiting, and diarrhea
Dizziness and headache
Skin rashes, urticaria, and injection site hematoma
Increased risk of bleeding in predisposed patients

Drug Interactions

Anticoagulants (heparin, oral anticoagulants): concomitant use may enhance anticoagulant effects and increase bleeding risk
Antiplatelet agents (aspirin, clopidogrel): potential synergistic increase in bleeding risk

Curated Content: Needs Vetting Before Put to Clinical Use